Tryptophan potentiates CD8+ T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation

Rui Qin,1 Chen Zhao,1 Chen-Ji Wang,1 Wei Xu,2,3 Jian-Yuan Zhao,2,3 Yan Lin,2,3 Yi-Yuan Yuan,2,3 Peng-Cheng Lin,4 Yao Li,1 Shimin Zhao,1,2 Yan Huang1

ABSTRACT

Background Tryptophan catabolites suppress immunity. Therefore, blocking tryptophan catabolism with indoleamine 2,3-dioxygenase (IDO) inhibitors is pursued as an anticancer strategy.

Methods The intracellular level of tryptophan and kynurenine was detected by mass spectrum analysis. The effect of tryptophan and IDO inhibitors on cell surface programmed cell death protein 1 (PD-1) level were measured by flow cytometry. A set of biochemical analyses were used to figure out the underlying mechanism. In vitro co-culture system, syngeneic mouse models, immunofluorescent staining, and flow cytometry analysis were employed to investigate the role of tryptophan and IDO inhibitor in regulating the cytotoxicity of CD8+ T cells.

Results Here, we reported that IDO inhibitors activated CD8+ T cells also by accumulating tryptophan that downregulated PD-1. Tryptophan and IDO inhibitors administration, both increased intracellular tryptophan, and tryptophanyl-riRNA synthetase (WARS) overexpression decreased Jurkat and mice CD8+ T cell surface PD-1. Mechanistically, WARS tryptophanylated lysine 1136 of and activated E3 ligase TRIP12 to degrade NFATc1, a PD-1 transcription activator. SIRT1 de-trypotamylation of TRIP12 and reversed the effects of tryptophan and WARS on PD-1. Tryptophan or IDO inhibitors potentiated CD8+ T cells to induce apoptosis of co-cultured cancer cells, increased cancer-infiltrating CD8+ T cells and slowed down tumor growth of lung cancer in mice.

Conclusions Our results revealed the immune-activating efficacy of tryptophan, and suggested tryptophan supplement may benefit IDO inhibitors and PD-1 blockade during anticancer treatments.

INTRODUCTION

Cancer cells express programmed death ligand 1 (PD-L1) on their surface and use it to interact with the T cell programmed cell death protein 1 (PD-1), a major regulator of T cell exhaustion that leads to the loss of T cell proliferative capacity and CD8+ T effector function,1 2 to escape an immune attack.3 Cancer immune therapy aims to either boost the body's natural immune defense or decrease immune escape of cancer cells.

Eliminating PD-L1 prevents immune escape of cancer cells. Blocking the PD-1 pathway restores T cell function and improves tumor eradication.4 Therefore, inhibitors of both PD-L1 and PD-1 are clinically used as drugs to treat cancers, such as melanoma, advanced lung cancer, kidney cancer, bladder cancer, and Hodgkin’s lymphoma.3

Tryptophan is an essential amino acid whose catabolism is extensively studied in cancer biology because of its close association with cancer and immune responses. The major tryptophan-catabalizing enzyme indoleamine-2,3-dioxygenase (IDO)5 is over-expressed in such cancers as gastric, colon, and renal cell carcinomas,6 tryptophan catabolism is critical for maintaining the immune privilege of the placenta,7 and blocking IDO with IDO inhibitors, such as l-isomer of methylated tryptophan (L1-MT), showed anti-cancer effects in preclinical models.5 8 9 As the rate-limiting enzyme, IDO converts >95% tryptophan into kynurenine.10 11 Moreover, downstream metabolites of tryptophan catabolism, such as kynurenine, act to suppress certain immune cells, probably via pro-apoptotic mechanisms.12 Thus, theories have been postulated to suggest that tryptophan catabolism is necessary for maintaining certain aspects of immune tolerance. However, mice T cells lacking general control non-derepressible 2, an amino acid sensor, are not susceptible to IDO-mediated anergy by dendritic cells in tumor-draining lymph nodes,13 suggesting that IDO may mediate immune response functions via tryptophan catabolites, and tryptophan itself. However, the immune activation effects of tryptophan accumulation, another possible outcome of IDO inhibition, have largely been ignored.

T lymphocytes are extremely sensitive to tryptophan shortage, which causes their
arrest in the G1 phase of the cell cycle. By depleting tryptophan in local tissue environments, IDO sensitizes T cells to apoptosis. IDO knockout (KO) in mice greatly sensitized them to PD-L1 antibody treatment to B16 melanoma tumor growth and increased overall survival. In patients with advanced non-small cell lung cancer, higher IDO activity could predict resistance to anti-PD-1 treatment. In advanced glioblastoma, IDO inhibition was reported to synergize PD-1 blockade to improve survival. All these facts suggest an intrinsic connection between IDO and PD-1, and a possibility of the inhibitory function of IDO via mediation of PD-1 expression. However, whether tryptophan shortage would induce PD-1 upregulation, an event that promotes T cell apoptosis, is yet to be revealed.

Besides being building blocks of biosynthesis, tryptophan and other amino acids are signaling molecules that regulate various biological processes through transfer RNA (tRNA) synthetase catalyzed lysine modifications in proteins. Thus, it is important to investigate whether tryptophan, in addition to its catabolites, is a regulator of immunity. In the current study, we report that tryptophan boosts the immunity of T cells, which decreases T cell surface PD-1 expression via tryptophanylation of E3 ligase TRIP12.

**MATERIALS AND METHODS**

**Plasmid constructs**

The TRIP12 complementary DNA (cDNA) (NM_001284214.2) was a generous gift from Jiahui Han’s lab (Xiamen University, China). TRIP12 cDNA was cloned into pCMV-flag or pCMV-myc vector. TRIP12 mutants were generated by Fast Mutagenesis Kit (Vazyme, Nanjing, China) following the manufacturer’s instructions. The pENTER-NFATc1-flag plasmid was purchased from Vigene Biosciences (Shandong, China) and NFATc1 (NM_172390.3) was subcloned into pCMV-myc vector. The pCMV ubiquitin (Ub)-HA, pcDNA3.1-WARS-flag, pcDNA3.1-SIRT1/2/3/4/5/6/7-HA plasmids were constructed previously in our laboratory. Tryptophanylation tRNA synthetase (WARS) (NM_173701.2) cDNA was cloned into pCMV-flag or pCMV-myc vector to obtain WARS expression plasmids. The sgRNAs for WARS/TRIP12 KO were inserted into pSpCas9(BB)-2A-Puro vector and the sgRNAs for TRIP12 knockin were inserted into pSpCas9(BB)-2A-GFP. All constructs were confirmed by sequencing.

**Antibodies**

**Commercial antibodies**

For human and mouse CD8+ T cell activation, antihuman CD3, antihuman CD28, antimouse CD3 and antimouse CD28 were purchased from Biolegend (San Diego, California, USA). For flow cytometry analysis, antimouse CD16/32, fluorescein isothiocyanate (FITC) antimouse CD45, APC antimouse CD3, Alexa Fluor 488 antimouse CD3, PerCP/Cyanine5.5 antimouse CD4, Brilliant Violet 421 antimouse CD8a, PE antimouse CD8a, PE antimouse CD1, APC antihuman CD3, FITC antihuman CD1, PE antihuman interferon (IFN)-γ, APC antihuman tumor necrosis factor (TNF)-α, PerCP/Cyanine5.5 antihuman granzyme B, PE antimouse perforin, zombie aqua, Alexa Fluor 700 antimouse anti-CD8, Alexa Fluor 647 antimouse TCR-β1, FITC antimouse KLH, and PE antimouse CD127 were purchased from Biolegend. eFluor450 antimouse TNF-α was purchased from eBiosciences (San Jose, USA). PE-Cy7 antimouse IFN-γ was purchased from BD Biosciences (San Diego, USA). For western blot analyses, anti-TRIP12 was purchased from Bethyl Laboratories (Montgomery, Texas, USA), anti-NFATc1 was from Santa Cruz Biotechnology (Shanghai, China), anti-WARS was from Proteintech (Hubei, China), anti-actin was from Sigma (St. Louis, Missouri, USA), anti-IDO1 was from Proteintech and Cell Signaling Technology (New England Biolabs, Ipswich, Massachusetts, USA), anti-HA-horseradish peroxidase (HRP) was from MBL (Nagoya, Japan), anti-flag-HRP, anti-myc-HRP was from GNI (Tokyo, Japan), HRP-conjugated goat antirabbit, HRP-conjugated goat antimouse were from Jackson ImmunoResearch (West Grove, Pennsylvania, USA). For immunofluorescence, antimouse CD4, antimouse CD8 were purchased from Biolegend, Alexa Fluor 647-affiniPure goat antirat IgG (H+L) was from Jackson ImmunoResearch. For immunoprecipitation, anti-flag M2 agarose beads were purchased from Sigma, anti-myc was from Abcam (Cambridge, Massachusetts, USA). Anti-PD-1 was purchased from Bio X Cell (clone RMP1-14, West Lebanon, New Hampshire, USA).

**Preparation and validation of tryptophanylation antibodies**

Antitryptophanylation antibody (TrpK) was customized from Abmart (Shanghai, China). It was raised in rabbits against the synthetic peptide containing tryptophanylated lysine residues (Ac-CGGGK(w)GGGGK(w)GGGGK(w)GGGG-NH2, TrpK-W). Rabbits were injected with the TrpK-W for 3 times and exsanguinated 10 days following the final boost. Tryptophanylation antibodies (anti-TrpK) from antisera were captured and purified.

To validate the anti-Trp-K, dot blot assays were conducted to test the reactivity of anti-Trp-K against TrpK-W and a synthetic peptide with identical amino acid sequence but devoid of tryptophanylation (Ac-CGGGKG-GGGGKKGGGG-NH2). The specificity of anti-Trp-K was tested by competing anti-Trp-K binding to TrpK-W with tryptophanylated bovine serum albumin, which was made according to a protocol described by Moellering and Cravatt. Briefly, the lysine tryptophanylation reactions were carried out at room temperature in a 2 mL reaction mix (2-(N-Morpholino)ethanesulfonic acid potassium salt (MES) base, pH 7.5) that contains 3.4 mg/mL tryptophanylation, 35 mg/mL L-(3-Dimethylaminopropyl)-5-ethylcarboxamide hydro (EDC) (Thermo Fisher Scientific, Waltham, Massachusetts, USA), and 40 mg/mL N-Hydroxy succinimide (NHS) (Thermo Fisher Scientific).
BSA solution was added to a final concentration of 1 mg/mL.

Cells
HEK293T, Jurkat T, CT26, Lewis lung carcinoma (LLC), and B16F10 cell lines were originally purchased from the Cell Bank of the Chinese Academy of Sciences.

Generation of WARS knockout, TRIP12 knockout, and knockin HEK293T cells
HEK293T-WARS-KO, HEK 293T-TRIP12-KO and HEK 293T-TRIP12-K1136R knockin cell lines were generated using CRISPR-Cas9 KO/knockin strategy. The sgRNAs were designed from the website (http://crispr.mit.edu) and then the sgRNAs for HEK293T-TRIP12/WARS-KO cells were inserted into pSpCas9(BB)-2A-Puro and the sgRNAs for HEK293T-TRIP12-K1136R knockin cells were inserted into pSpCas9(BB)-2A-GFP vector.

Donor DNA for HEK293T-TRIP12-K1136R knockin was constructed by the following method: The 2199 bp fragments spanning from 1140 bp upstream and 1056 bp downstream with site K1136R (AAA) of TRIP12 gene were amplified from genomic DNA which was extracted from HEK293 cells, and cloned into pCMV-flag vector. K1136 AAA was mutated into K1136R CGC using Mut Express II Fast Mutagenesis Kit V2 (Vazyme).

HEK293T cells were transfected with the constructed plasmid using Lipofectamine 3000 (Thermo Fisher Scientific). Two days later, HEK293T-TRIP12/WARS-KO cells were selected with 2 µg/mL puromycin (sigma) for a week and GFP-positive HEK293T-TRIP12-K1136R knockin cells was isolated by fluorescence-activated cell sorting. Single cell clones were then obtained in 96-well plates. KO and knockin cells were verified by sequencing and western blot analysis.

Preparation of mouse CD8+ T cells
Mice were sacrificed by rapid cervical dislocation and the body surface was sterilized in 75% alcohol. Maintaining in a sterile environment, spleen without extra fat was dissociated and collected using sterile forceps and scissors. The spleens were washed by phosphate buffered saline (PBS) and crushed to isolate spleen cells by grinding the spleens with a syringe plunger against 70 µm nylon mesh filter, centrifugated at 2000 rpm for 10 min, washed with RPMI 1640 medium containing 50% fetal bovine serum (FBS). Then, 10 µL matching streptavidin nanobeads were added into the above mixture and incubated for 15 min. Then, 2.5 mL MojoSort buffer was added, the mixture was transferred to the flow cytometry tube and the tube was placed in the magnet for 5 min. Finally, the liquid which contains mouse-naive CD8+ T cells were collected.

For specific cytoxicity assays, CD8+ T cells from OVA-immunized BALB/c mice were acquired by flow cytometry cell sorting. Briefly, unconjugated antimouse CD8/32 was used for blocking Fc receptors. After stained by antimouse CD3 and CD8 for 30 min, splenocytes was washed 3 times and resuspended using staining buffer. Finally, CD3+CD8+ dual positive cells were selected by flow cytometric cell sorting.

Cells culture and plasmid transfection
HEK293T, LLC, and CT26 cells were cultured in complete Dulbecco’s Modified Eagle Medium medium (HyClone, Logan, Utah, USA) supplemented with 10% FBS (Bioind, Israel) and antibiotics (100 µg/mL streptomycin and 100 units/mL penicillin, Gibco, Paisley, UK), Jurkat T cells were cultured in RPMI 1640 medium (HyClone) containing 10% FBS and streptomycin/penicillin. Mouse CD8+ T cells were cultured in complete RPMI 1640 medium containing 10% FBS, antibiotics and interleukin (IL)-2 (10 ng/mL). All cells were maintained at 37°C in humidified 5% CO2.

Plasmids were transfected into adherent cells using polyethylenimine (PEI) (1 µg/µL, Polysciences, Warrington, USA), small interfering RNAs (siRNAs) were transfected into adherent cells by HilyMax (Dojindo Molecular Technologies, Kumamoto, Japan). Transfection of Jurkat T was performed through electroporation by Lonza Amaxa Nucleofector 2B (Lonz, Basel, Switzerland) with program S-018.

T cells activation
Cell culture plates were pre-coated with anti-CD3 and anti-CD28 antibodies at 4°C overnight, and then washed 3 times with RPMI 1640 medium. Jurkat T or mouse-naive CD8+ T cells were activated with the pre-coated plates for 2 days.

Jurkat T cell proliferation
Proliferation was measured by flow cytometry using carboxyfluorescein diacetate succinimidyl ester (CFSE) (eBioscience). Briefly, Jurkat cell suspensions (1×10^7 cells) were prepared and labeled with 0.5 µM CFSE at 37°C for 10 min, washed with RPMI 1640 medium containing 50% FBS, and then resuspended in pre-warmed cell culture medium containing 10% FBS. Forty-eight hours later, dividing cells were detected by flow cytometry and cell proliferation was quantified by CFSE dilution.

Cell treatments
IDO inhibitors
For IDO inhibitors treatment, Jurkat T cell were treated with indoximod (CAS No. 110117-83-4), epacadostat (CAS No. 1204669-58-8) or NLG919 analog (CAS No. 1402836-58-1) (Selleck Chemicals, Houston, Texas, USA) for 6–8 hours in different concentration as indicated in the figures or legends.
Tryptophan starvation

Tryptophan starvation was performed in HET293T, Jurkat T cells, and mouse CD8⁺ T cells. Cells were cultured in Trp-free RPMI 1640 medium (Yeasten Biotechnology, Beijing, China) at 37°C in humidified 5% CO₂.

Me-Trp and kynurenic acid supplementation

Cells were first Trp-starved for 2 hours, and then cultured in the medium supplemented with Me-Trp in different concentrations as indicated in the figures or legends for 4–6 hours. Kynurenic acid supplementation was performed in the same way as that of tryptophan supplementation.

Tryptamine and nicotinamide treatments

As for tryptamine and nicotinamide (NAM) treatments, cells were cultured in normal medium supplemented with tryptamine in different concentrations as indicated in the figures or legends or NAM (5 mM) for 6 hours.

NFATc1 half-life analyses and MG132 treatments

To analyze half-life of NFATc1, the culture growth medium was replaced with normal growth medium containing 50 µg/mL cycloheximide, and collected at different time points (0, 1, 2, 4 hours). To inhibit proteasomal degradation of NFATc1, cells were treated with normal growth medium containing 20 µM MG-132 for 6 hours.

Reverse transcription quantitative PCR

Total RNA for reverse transcription quantitative PCR (RT-qPCR) was extracted using Trizol reagent. Following the manufacturer’s instruction, RT was performed with PrimeScript RT reagent kit (Takara, Tokyo, Japan) and qPCR was performed using AceQ qPCR SYBR Green Master Mix (Vazyme). Quantitative analysis of qPCR was carried out by 2^(-ΔΔCt) method used actin as the internal reference indicator.

Western blot analysis

Cells were lysed with sodium dodecyl sulfate (SDS) protein sample loading buffer or lysed in 0.5% NP-40 lysis buffer (50 mmol/L Tris-HCl, 150 mmol/L NaCl, 0.5% NP-40, pH=7.2–7.4, protease inhibitors cocktail tablets (Roche)) for 30 min at 4°C, then incubated with anti-flag beads (Sigma) to enrich the target protein overnight at 4°C. For immunoprecipitation of TRIP12-myc protein, the cell lysates were first incubated with anti-myc antibody overnight at 4°C, followed by 4 hours incubation with protein A/G plus-agarose beads. The beads were then washed vigorously with immunoprecipitation lysis buffer for 6–8 times. The protein was eluted by boiling the beads with SDS loading buffer for 5 min, and then subjected to western blot analysis.

In vivo ubiquitination assay

Plasmids ubiquitin-Flag, NFATc1-Flag, and TRIP12-WT-myc, or TRIP12-K1136R/W-myc, or TRIP12-ΔHECT-myc were co-transfected into HEK293T cells. The HEK293T cells were treated with 20 µM MG-132 for 6 hours before harvest. NFATc1 was purified by co-immunoprecipitation using anti-flag-conjugated agarose beads (Sigma), followed by western blot analysis. To examine the effect of WARS on ubiquitination of NFATc1, siWARS were co-transfected with ubiquitin-HA, NFATc1-flag, and TRIP12-WT-myc in HEK293T cells. Alternatively, WARS were reintroduced into HEK293T-WARS KO cells by co-transfection with ubiquitin-HA, NFATc1-flag, and TRIP12-WT-myc.

Mice tumor models

Female C57BL/6 mice aged 4 weeks were purchased from SLAC Laboratory Animal (Shanghai, China). The
mice were housed in a standard environment and fed with a standard diet during a 1-week adaptation period. The LLC cells or B16F10 cells of logarithmic phase were harvested, and single cell suspensions were prepared. Healthy female C57BL/6 mice, weighing 18–20 g, were subcutaneously inoculated in the left axillae with \(5 \times 10^6\) LLC cells or B16F10 cells. The day after inoculation, the mice were randomly divided into four groups, 10 mice in each group. For LLC-inoculated mice, the Me-Trp group received an intraperitoneal injection of Me-trypophan solution (=150 mg/kg, dissolved in PBS), and indoximod group received an intraperitoneal injection of indoximod suspension liquid (=100 mg/kg, dissolved in NaOH solution, pH adjusted to 7.2–7.4). The Me-Trp and indoximod group were intraperitoneally injected with both Me-Trp (=150 mg/kg, dissolved in PBS) and indoximod (=100 mg/kg). The corresponding control mice received an equivalent volume of PBS. All the injections were performed twice per day (09:00 and 17:00 hours). For B16F10-inoculated mice, Me-Trp and control group were the same as that in LLC-inoculated mice. Anti-PD-1 (10 mg/kg) were administered by intraperitoneal injections on days 3, 6, 9, and 12 after inoculation in anti-PD-1 group. The anti-PD-1 and Me-Trp group was injected with both anti-PD-1 and Me-Trp. Tumor sizes were measured 2 or 3 times a week by randomizing the order, with each mouse tested within an hour on the same day. The tumor volume was calculated by the following formula: tumor volume = \(0.5 \times \) tumor length \(\times\) tumor width \(\times\) tumor width. Mice were excluded if they died or if their tumors ruptured, or if the tumor volume exceeded 1 cm\(^3\). The tumor-bearin mice were sacrificed by cervical dislocation. Tumors and spleen were carefully removed, and tumors were weighed and photographed.

**Flow cytometry**

**Surface staining of PD-1**

For the preparation of mice-naive CD8\(^+\) T cells, or CD8\(^+\) cells from OVA-immunized mice, or tumor-infiltrating CD8\(^+\) T cells from CLL-bearing mice, splenocytes were obtained with the same method as described above. Mouse tumors were minced with scissors and subjected to enzymatic digestion with 2 mg/mL collagenase type I (Stem Cell Technologies, Vancouver, Canada) in 37°C with shaking for 2 hours, and cells were filtered through a 70 µm nylon mesh filter. To analyze the PD-1 surface expression of mouse CD8\(^+\) T cells, cell aggregates, small debris and dead cells were excluded on the basis of forward-scatter and side-scatter, then leukocytes were distinguished by a CD45\(^+\) cell gate, then T cells were distinguished by a CD3\(^+\) cell gate, then a CD8\(^+\) cell gate was used to define CD8\(^+\) T cells using Beckman Coulter Gallios flow cytometer (Fullerton, California, USA). Compensation was made according to single staining. The mouse CD8\(^+\) cells were blocked by anti-CD16/32 at 4°C for 10 min, then stained with antibody against PD-1 at 4°C for 30 min before subjecting to flow cytometer. As for Jurkat T cells, PBS containing 5% FBS was used for blocking. After cell aggregates, small debris and dead cells were excluded on the basis of forward-scatter and side-scatter, a single stain of PD-1 surface expression of Jurkat T was analyzed by FlowJo software (Tree Star, San Carlos, California, USA). Cells stained with isotype control antibody were considered as negative control. Percentage of PD-1-positive mice was determined in comparison to isotype control antibodies. The PD-1 mean fluorescence intensity (MFI) was calculated.

**Intracellular staining of IL-2, TNF-α, and IFN-γ, granzyme B, and perforin**

Activated Jurkat T cells were treated with brefeldin A for 6 hours before collecting, fixed in 4% paraformaldehyde for 20 min at room temperature, permeabilized with intracellular staining wash buffer (Biolegend), cells were blocked with PBS containing 5% PBS, IL-2, TNF-α, IFN-γ were then stained.

Splenocytes were subjected to erythrocyte lysis buffer and prepared by passing spleen tissue through a 70-µm cell strainer, and then treated by cell stimulation cocktail (eBioscience) and brefeldin A (Biolegend) for 6 hours. After stained with zombie aqua and the surface markers, splenocytes were fixed in fixation buffer (Biolegend) for 20 min at room temperature, permeabilized with intracellular staining wash buffer, blocked with anti-CD16/32, and then stained with anti-IFN-γ, granzyme B, and perforin.

Appropriate isotype controls were used, and compensation was made according to single staining. Percentage of positive cells and MFI were analyzed with FlowJo software (Tree Star).

**Immunofluorescence**

Tumors removed from sacrificed mice were fixed for 3 days with 4% paraformaldehyde at 4°C, and then placed in 30% sucrose solution for 2 days for dehydration. The samples and cryostat microtome were prechilled to –20°C, and then tumor sections (45 µm) were cut on a cryostat microtome, blocked with 5% goat serum in PBS containing 0.1% Triton X-100 for 2 hours, and then incubated with primary antibodies (CD4, 1:150; CD8, 1:150) in blocking buffer overnight. Subsequent to the excess primary antibody being washed off, sections were incubated with Alexa Fluor 647-labeled goat antirat IgG (Jackson ImmunoResearch, 1:200) and DAPI for 3 hours. The sections were sealed with antifluorescence quencher. After standing for a few days, fluorescence was visualized and images along the z-axis (z-axis interval: 2 µm) were captured by Olympus FV3000 inverted confocal microscope (Centre Valley, Pennsylvania, USA) equipped with a 40× objective lens. The cell number of positive signals per cubic millimeter was calculated.

**Cytotoxicity assays**

For specific cytotoxicity assays, CD8\(^+\) T cells isolated from OVA-immunzed BALB/c mice were used as effector cells. Emulsified OVA protein was injected into BALB/c mice by three subcutaneous injections at 1-week or 2-week intervals.
CD8+ T cells were obtained from spleens by flow cytometric sorting with surface markers CD3 and CD8. Then CD8+ T cells were treated with tryptophan in different concentrations. Target mouse cancer cell lines LLC and CT26, which were placed in the U-type 96-well plate in advance, were soaked with 10 µM OVA peptide (SIINFEKL) at 37°C for 1 hour. Excess OVA peptide was washed away by RPMI 1640 medium, then CD8+ T cells were added and co-cultured with target cancer cells at E:T ratios of 10:1. Subsequently, floating CD8+ T cells from the supernatant were washed off by PBS, the remaining adherent cancer cells were digested by 0.25% trypsin, washed by PBS for 3 times, and stained using an annexin-V-FITC/propidium iodide apoptosis kit (TaKaRa, Dalian, China). Apoptosis of target cancer cells was measured with Beckman Coulter Gallios flow cytometer to reflect the cytotoxicity ability of CD8+ T cells. A CD3 staining was used to distinguish CD3− cancer cells and the remaining CD3+ CD8+ T cells.

**T cells adoptive transfer**

For adoptive T-cell transfer, CD8+ T cells were isolated from spleens and lymph nodes of ovalbumin-transgenic (OT-I) mice (kindly provided by Dr Xiaolei Yu of Fudan University) with mouse CD8+ T cells isolation kit (Biolegend, San Diego, California, USA), and then transferred into recipient C57BL/6 WT mice (2×10^6 cells/mouse) by intravenous injection. The next day, each mouse was immunized by subcutaneous multiple-point injections with 20 µg OVA (Sigma-Aldrich) diluted in 100 µL PBS that mixed with 100 µL complete Freund’s adjuvant (Sigma-Aldrich). Me-Trp (150 mg/kg) or indoximod (100 mg/kg) was administered by intraperitoneal injections twice a day. NFAT inhibitor VIIVIT peptide (10 mg/kg) (MCE, Monmouth Junction, New Jersey, USA) was intraperitoneally injected once a day. All the treatments were started 1 day before adoptive transfer (day 0) until sacrifice.

**In vivo T cell differentiation**

Day 8 after adoptive transfer, splenocytes were obtained and stained with zombie aqua (Biolegend), anti-CD8 (Biolegend), anti-TCR-Vα2 (Biolegend), anti-KLRG1 (Biolegend), and anti-CD127 (Biolegend). Short-lived effector CD8+ T cells and memory precursor effector cells were distinguished by KLRG1 and CD127 staining.

**SIRT1 knockout mice**

Whole-body SIRT1 knockout (SIRT1-KO) mice and the corresponding control mice were generated by the Cre/loxP recombination system. SIRT1-KO mice (Cre−/SIRT1loxP/loxP) were generated by crossing homologous SIRT1loxP/loxP (Southern Model Organisms, Shanghai, China) with UBC-Cre-ERT2 mice (Southern Model Organisms). The control mice (wild type (WT)) were SIRT1loxP/loxP (Cre negative). Activation of Cre recombinase was induced by intraperitoneal injection of tamoxifen (Sigma). Tamoxifen was dissolved in corn oil containing 10% ethanol (20 mg/mL) at 37°C, stored at −20°C and protected from light. Each mouse was administered 100 µL of tamoxifen solution per day for seven consecutive days by intraperitoneal injection. Mice were tested after a recovery period of at least 1 week after the final tamoxifen injection to permit deletion of the SIRT1 gene and degradation of residual SIRT1 and SIRT1 messenger RNA (mRNA). PCR and western blot analysis were used to confirm the efficiency of Cre-loxP-mediated SIRT1 deletion in splenic tissue. The DNA was extracted from splenic tissue using Genomic DNA Extraction Kit (TIANGEN, Shanghai, China) according to the manufacturer’s protocol, and then PCR was performed to identify mice with Cre recombinase and SIRT1 loxP sites.

**Oligonucleotides**

| siRNA TRIP12A | GACAAAGACUAUUACAAAUUU |
| siRNA TRIP12B | GAACACAGAUGGUGCAUUAAU |
| siRNA NFATc1-A | CCGUUCACGUACGUUUUCA |
| siRNA NFATc1-B | CGAGCCGUACUUGACUGGC |
| siRNA WARSA | CAGGGAUCUUAUACUUAGAdTdT |
| siRNA WARSB | GGUUUCAUGCAACGUAUAdTdT |
| CRISPR/ Cas9-mediated TRIP12 gene KO sgRNA-A | CACCGAAACACAAACGACTCAAT |
| CRISPR/ Cas9-mediated TRIP12 gene KO sgRNA-B | CACCGCTGGAACAAACCTCTTGAC |
| CRISPR/ Cas9-mediated WARS gene KO sgRNA | CACC GAACCTCCCCAGCGTACCC |
| CRISPR/ Cas9-mediated TRIP12-K1136R gene knockin sgRNA-A | CACCGTAAAAGGTGGTGAATAGGAC |
| CRISPR/ Cas9-mediated TRIP12-K1136R gene knockin sgRNA-B | CACCGCTTTGTAGAGAAAAAAATTA |
| Q-PCR NFA1-1F | AAAACTGACCGGGACCTGTG |
| Q-PCR NFA1-1R | GCTCATGTTCACGCTTACG |
| Q-PCR PD-1F | CCCAGATGTTGTCTTATAGCTCC |
| Q-PCR PD-1R | TTACGAGAAGGCTCCGAGT |
| Q-PCR actinF | CCTCTCCCAAGTCCCAGCAG |
| Q-PCR actinR | GGGCAAGAGGCTCATCAT |

**Statistical analysis**

Statistical analyses and graphs were undertaken using GraphPad Prism V.8.0 (GraphPad Software, San Diego, USA). The mean values±SD of independent experiments triplicates and every data point were shown in graph. Unpaired two-sided Student’s t-test was used to reflect the difference between two groups. Results in figures 1B, online supplemental figure S1A–H, S2B–H, S3A, S3C–G, S3J, S4G–H, S6A–C, S6E, 7A–B, 7I are representative data of three independent repeats. And there were similar results in three independent repeats.

**RESULTS**

**Tryptophanyl-tRNA synthetase-dependent downregulation of PD-1 expression by tryptophan**

In immortalized anti-CD3 and anti-CD28 antibodies co-stimulated Jurkat cells (online supplemental figure S1A), L-methyl-tryptophan ester (Me-Trp) administration
Figure 1  Tryptophan tryptophanyl-tRNA synthetase (WARS)-dependently downregulated programmed cell death protein 1 (PD-1) expression. (A) Me-Trp administration increases intracellular tryptophan. Anti-CD3 and anti-CD28 antibodies co-stimulated Jurkat T cells were supplemented with 73.5 μM L-methyl-Trp in the culture media. The levels of intracellular tryptophan were detected by liquid chromatography-mass spectrometry. n=3, mean±SD. Knockdown WARS abrogated cell surface PD-1 regulation by Me-Trp. The cell surface PD-1 levels were detected by mean fluorescence intensity (MFI, herein after) and percentage of PD-1+ cells in Jurkat cells and Jurkat cells with WARS knocked down by small interfering RNAs (siRNAs) when Me-Trp supplemental (B) or tryptophan-deprivation (C) were applied to cells. All levels were compared with that of Jurkat cells without treatment. n=3, mean±SD. Silencing NFATc1 diminished WARS ability to alter cell surface PD-1. The PD-1 expression levels were detected in Jurkat T cells and NFATc1 knockdown Jurkat T cells under either WARS overexpression (D) or WARS knockdown (E). MFI levels and PD-1-positive cell levels were calculated and compared with that of the controls. n=3, mean±SD. Pyrophosphate (ppi) inhibited Me-Trp supplemental and tryptophan-starvation to alter PD-1. The PD-1 expression levels were detected in stimulated Jurkat T cells that were cultured in media supplemented with Me-Trp (F) or with tryptophan deprived (G) under presence or absence of ppi (10 mM final concentration) in the culture media. n=3, mean±SD. (H) Me-Trp administration decreased mouse CD8⁺ T cells surface PD-1. Mouse-naive CD8⁺ T cells were isolated and activated by anti-CD3/CD28 antibodies (5 μg/mL). The CD8⁺ T cells surface PD-1 expression levels were detected when they were cultured in media with indicated Me-Trp levels. n=3, mean±SD. *P<0.05, **p<0.01, ***p<0.001, two-tailed Student’s t-test.

in culture media at 73.5 μM increased intracellular tryptophan by 446.1% (figure 1A), and decreased the cell surface PD-1 by 37.00% (figure 1B). In contrast, depriving the culture media of tryptophan upregulated PD-1 by 50.93% (figure 1C, online supplemental figure S1B). These results suggest that tryptophan or its catabolites negatively regulate PD-1 expression in Jurkat cells. Since tryptophan can modify lysine residues in proteins and regulate protein functions,19 we investigated whether tryptophan inhibited PD-1 expression through lysine tryptophanylation. Overexpression of WARS, the proven lysine tryptophanyl transferase,19 phenocopied tryptophan to decrease cell surface PD-1 in Jurkat T cells (figure 1D, online supplemental figure S1C). Conversely, silencing WARS with siRNAs increased surface PD-1 level (figure 1E, online supplemental figure S1D). Administration of
cells with general aminoacylation inhibitor pyrophosphate resulted in PD-1 increasing on Me-Trp supplemental (figure 1F, online supplemental figure S1E) and Trp deprivation (figure 1G, online supplemental figure S1F). These findings suggest that WARS-mediated lysine tryptophanlylation likely repressed PD-1 expression.

Me-Trp decreased anti-CD3 and anti-CD28 antibodies activated the cell surface PD-1 in mouse CD8+ T cells (figure 1H, online supplemental figure S1G and S1H. Notably, when WARS was silenced by siRNAs, the PD-1 altering potencies of Me-Trp administration (figure 1B) and tryptophan deprivation (figure 1C and online supplemental figure 1B) on surface PD-1 expression were reduced, further supporting that the effects of Trp on PD-1 are mediated by WARS.

IDO inhibitors decreased PD-1 expression by accumulating intracellular tryptophan

The fact that T lymphocytes are extremely sensitive to tryptophan shortage and IDO sensitizes T cells to apoptosis promoted us to examine T cells such as T lymphocyte Jurkat cells express IDO1, as previous studies obtained negative results. After activated with anti-CD3 and anti-CD28 antibodies, the levels of IDO1 mRNA increased by >80 folds and the expression of IDO1 was detectable by western blot analysis (online supplemental figure S2A), consistent with a report that Jurkat cells actually expressed IDO1 and explained, at least partially, that T cells sensitive to tryptophan levels. As PD-1 expression is restricted to immune cells. We examined a hypothesis that IDO inhibitors may decrease PD-1 expression by elevating intracellular tryptophan levels. Using the IDO inhibitors, namely indoximod, epacadostat, and NLG919 analog at appropriate concentrations increased tryptophan levels and left kynurenine levels negligibly affected in Jurkat T cells (figure 2A), phenocopied Me-Trp supplementation (figure 1B) to decrease the cell surface PD-1 expression in the anti-CD3-activated and anti-CD28-activated Jurkat T cells (figure 2B, online supplemental figure S2B). These, together with that kynurenine had a negligible effect on surface PD-1 expression in Jurkat T cells (figure 2C and online supplemental figure S2C), suggested that tryptophan rather than its catabolites, negatively regulates surface PD-1 expression of Jurkat T cells. Moreover, indoximod has previously been shown to affect T cell function through affecting mammalian target of rapamycin complex 1 (mTORC1) signaling. We tested whether indoximod effects on PD-1 can be independent of mTORC1. Indoximod still able to regulate PD-1 expression (online supplemental figure S2D) when mTORC1 signaling was inhibited by rapamycin in Jurkat cells (online supplemental figure S2E), suggested indoximod may regulate PD-1 in mTORC1-independent mechanisms.

The cell surface PD-1 expression decreasing effects of IDO inhibitors were recaptured in naïve CD8+ T cells, isolated from the spleens of BALB/c mice, that were co-treated with anti-CD3 and anti-CD28 antibodies for 48 hours (figure 2D and online supplemental figure S2F). These results suggest that tryptophan decreases surface PD-1 levels through a mechanism other than tryptophan catabolism.

IDO inhibitors increased the levels of IL-2, IFN-γ, and TNF-α, indicators of T cell activation, in activated Jurkat cells (figure 2E and online supplemental figure S2G) and in mouse CD8+ T cells (figure 2F). These results were consistent with the decrease in PD-1 expression by immunosuppressive tryptophan catabolites.

Tryptophan and WARS downregulated PD-1 transcription factor NFATc1

RT-qPCR revealed that the mRNA level of PD-1 was decreased by both Me-Trp and IDO inhibitors treatments in Jurkat cells (figure 3A), suggesting that Me-Trp and IDO inhibitors decrease PD-1 expression level, at least in part, by altering PD-1 transcription. We tried to identify transcription factors of PD-1 that may be regulated by Me-Trp and IDO inhibitors. Protein levels (figure 3B), but not mRNA levels (figure 3C), of NFATc1, a reported transcription factor for PD-1 that was confirmed by us (online supplemental figure S3A), were downregulated by Me-Trp supplementation in the culture media for activated Jurkat T cells. Furthermore, tryptophan deprivation of culture media of activated Jurkat T cells increased the protein levels (figure 3D), but not mRNA levels (figure 3E), of NFATc1 of Jurkat cells. These, together with that IDO inhibitors decreased NFATc1 (online supplemental figure S3B) and the cell surface PD-1 expression (see figure 2B), indicate that NFATc1 is regulated by tryptophan and IDO inhibitors, for decreasing cell surface PD-1.

Notably, WARS overexpression, a manipulation that may increase protein tryptophanylation, decreased NFATc1 protein levels (figure 3F), but not NFATc1 mRNA levels (figure 3G), of Jurkat cells. Moreover, WARS knockdown by siRNAs increased NFATc1 protein levels (figure 3H), but not NFATc1 mRNA levels (figure 3I), of Jurkat cells. These results suggest that tryptophanylation regulates NFATc1 at post-transcription levels. Furthermore, NFATc1 knockdown, which decreased surface PD-1 expression of Jurkat cells (online supplemental figure S3A), abrogated Me-Trp supplementation (figure 3J, online supplemental figure S3C) to decrease surface PD-1 in Jurkat T cells, indicating that tryptophanylation regulates surface PD-1 expression through NFATc1. These, together with that NFATc1 knockdown abrogated WARS overexpression and IDO inhibitors to decrease surface PD-1 in Jurkat T cells (figure 1D and online supplemental figure 1C figure 2B and online supplemental figure 2B), confirmed that decreased NFATc1 is the major reason for these manipulations to downregulate surface PD-1 expression.

Compared with that inhibiting NFAT with VIVIT peptide, which had no effect on T cell proliferation (online supplemental figure S3D), inhibited IL-2, TNF-α, and IFN-γ production (online supplemental figure S3F), tryptophan supplemental increased IL-2, TNF-α, and IFN-γ production and proliferation (online supplemental figure S3E, S3G) in Jurkat cells. The differences between NFAT inactivation and tryptophan treatment was likely due to that besides decreasing NFATc1 and PD-1 expression to activate T cells, tryptophan supplemental may alter IDO-mediated immnosuppression, which was consistent with the finding...
Figure 2  Indoleamine 2,3-dioxygenase (IDO) inhibitors decreases programmed cell death protein 1 (PD-1) through accumulating intracellular tryptophan. (A) IDO inhibitors altered intracellular levels of both tryptophan and kynurenine. Intracellular levels of tryptophan and kynurenine of Jurkat T cells and IDO inhibitors-treated Jurkat T cells were detected by liquid chromatography-mass spectrometry. The final concentrations of IDO inhibitors for indoximod (Ind) were: 0, 10, 50 µM; for epacadostat (Epa) were: 0, 0.3, 1 µM; and for NLG919 analog (NLG) were: 0, 0.1, 1 µM, respectively. (B) NFATc1 knockdown prevented IDO inhibitors to decrease PD-1. Cell surface PD-1 mean fluorescence intensity (MFI) and PD-1-positive levels were measured for Jurkat T cells and NFATc1 knockdown Jurkat T cells that were cultured with presence of indicated levels IDO inhibitors in the culture media. The final concentrations of IDO inhibitors for indoximod (Ind) were: 0, 1, 10, 50 µM; for epacadostat (Epa) were: 0, 0.3, 1, 3 µM; and for NLG919 analog (NLG) were: 0, 0.025, 0.1, 1 µM, respectively (herein after for all dose-dependent experiments of IDO inhibitors in Jurkat T cells). (C) Kynurenine did not affect surface PD-1 expression. Relative cell surface PD-1 MFI levels were measured for Jurkat T cells that were cultured in media supplemented with indicated levels of kynurenine. (D) IDO inhibitors decreased PD-1 in mouse CD8+ T cells. Relative cell surface PD-1 MFI levels and PD-1-positive levels were measured for mouse CD8+ T cells that were cultured with presence of different levels IDO inhibitors in the culture media. The final concentrations of IDO inhibitors for indoximod (Ind) were: 0, 1, 10, 50 µM; for epacadostat (Epa) were: 0, 0.3, 1, 3 µM; and for NLG919 analog (NLG) were: 0, 0.025, 0.1, 0.2 µM, respectively (herein after for all dose-dependent experiments of IDO inhibitors in mouse CD8+ T cells). IDO inhibitors increased interleukin (IL)-2, interferon (IFN)-γ, and tumor necrosis factor (TNF)-α levels in T cells. The IL-2, IFN-γ, and TNF-α levels were detected in stimulated Jurkat T cells, IDO inhibitors-treated Jurkat T cells by flow cytometry (E), in mice CD8+ T cells, and IDO inhibitors-treated mice CD8+ T cells by ELISA (F). *P<0.05, **P<0.01, ***P<0.001; ns, not significant.
that elevation in circulating tryptophan levels overcome IDO1-mediated immunosuppression in the tumor, along with the IFN-γ mRNA increasing. However, as activated T cell express high levels of IL-2, IFN-γ, and TNF-α, which were confirmed in Jurkat (figure 2E and online supplemental figure S2G) and in mouse CD8+ T cells (figure 2F), the increased cytokines in IDO inhibitors may be consequences of T cell activation, a notion that was supported by the fact that both indoximod, epacadostat, NLG919 analog, or Me-Trp. Me-Trp supplemental and WARS overexpression decreased the protein level of NFATc1. The protein (B) and mRNA (C) levels of NFATc1 were detected for activated Jurkat T cells that were cultured in media supplemented with levels of Me-Trp. n=3, mean±SD. Tryptophan starvation increased protein levels of NFATc1. The protein (D) and mRNA (E) levels of NFATc1 were detected at indicated time for activated Jurkat T cells that were cultured in tryptophan-deprived media. n=3, mean±SD. WARS overexpression decreased protein levels of NFATc1. The protein (F) and mRNA (G) levels of NFATc1 were detected in both activated Jurkat T cells and WARS-overexpression activated Jurkat T cells. WARS knockdown increased protein levels of NFATc1. The protein (H) and mRNA (I) levels of NFATc1 were detected in both activated Jurkat T cells and WARS-knockdown activated Jurkat T cells. (J) NFATc1 knockdown abrogated Me-Trp to decrease the cell surface PD-1. The MFI and PD-1-positive Jurkat T cells were detected in Jurkat and NFATc1 knockdown Jurkat cells that were cultured under different levels of Me-Trp. *P<0.05, **p<0.01, ***p<0.001; ns, not significant.

E3 ligase TRIP12 degraded NFATc1 and downregulated PD-1 expression

Proteasome inhibitor MG132 treatment on anti-CD3 and anti-CD28 antibodies co-stimulated Jurkat T cells resulted in elevated NFATc1 protein levels (figure 4A), suggesting that NFATc1 is subject to proteasomal degradation. Moreover, as MG132 supplementation blocked tryptophan supplementation (online supplemental figure S4A), WARS overexpression (online supplemental figure S4B) and IDO inhibitors (online supplemental figure S4C) decreased NFATc1 levels in Jurkat T cells, suggesting that tryptophanlylation regulates NFATc1 levels by altering its proteasomal degradation.

Searching the tryptic peptide library of human liver cancer tissue revealed that lysine 1136 of TRIP12, an E3 ligase, was tryptophanylated (figure 4B), suggesting that TRIP12 may be regulated by tryptophanlylation. TRIP12 co-immunoprecipitated with NFATc1, when they were co-expressed in HEK293T cells (figure 4C,D). The half-life of endogenous NFATc1 was prolonged by knockdown of TRIP12 (figure 4E). Deleting TRIP12 from HEK293T cells (online supplemental figure S4D) decreased the ubiquitination of ectopically expressed NFATc1 (figure 4F). Knockdown of TRIP12 in Jurkat T cells increased endogenous levels of NFATc1 protein (figure 4E). Furthermore, overexpressing TRIP12, but not a catalytically

![Figure 3](http://jitc.bmj.com/)

**Figure 3** Tryptophan and tryptophanyl-tRNA synthetase (WARS) downregulates programmed cell death protein 1 (PD-1) transcription factor NFATc1. (A) Me-Trp and indoleamine 2,3-dioxygenase (IDO) inhibitors decreased the messenger RNA (mRNA) level of PD-1 in Jurkat T cells. The PD-1 mRNA levels of anti-CD3 and anti-CD28 antibodies co-stimulated Jurkat T cells were detected with reverse transcription quantitative PCR (RT-qPCR) when the cells were treated with different levels of indoximod, epacadostat, NLG919 analog, or Me-Trp. Me-Trp supplemental and WARS overexpression decreased the protein level of NFATc1. The protein (B) and mRNA (C) levels of NFATc1 were detected for activated Jurkat T cells that were cultured in media supplemented with indicated levels of Me-Trp. n=3, mean±SD. Tryptophan starvation increased protein levels of NFATc1. The protein (D) and mRNA (E) levels of NFATc1 were detected at indicated time for activated Jurkat T cells that were cultured in tryptophan-deprived media. n=3, mean±SD. WARS overexpression decreased protein levels of NFATc1. The protein (F) and mRNA (G) levels of NFATc1 were detected in both activated Jurkat T cells and WARS-overexpression activated Jurkat T cells. WARS knockdown increased protein levels of NFATc1. The protein (H) and mRNA (I) levels of NFATc1 were detected in both activated Jurkat T cells and WARS-knockdown activated Jurkat T cells. (J) NFATc1 knockdown abrogated Me-Trp to decrease the cell surface PD-1. The MFI and PD-1-positive Jurkat T cells were detected in Jurkat and NFATc1 knockdown Jurkat cells that were cultured under different levels of Me-Trp. *P<0.05, **p<0.01, ***p<0.001; ns, not significant.
TRIP12 interacts with NFATc1. TRIP12 was tryptophanylated. A MS/MS spectrum from human liver protein library matched a tryptophanylated TRIP12 peptide.

KO increased NFATc1 protein levels in HEK293T cells (online supplemental figure 4E). Furthermore, TRIP12 cells, consistent with reduced expression of NFATc1, showed augmented ubiquitination of NFATc1 (figure 4H) in HEK293T knockdown Jurkat T cells at different time points after cycloheximide (CHX) treatments to block protein synthesis. Relative NFATc1 expression was measured against those of the untreated cells. (F) Cells were transfected with siTRIP12 for 48 hours, followed by 50 µg/mL CHX treatment for 1, 2, and 4 hours. Relative NFATc1 messenger RNA (mRNA) and surface PD-1 protein levels were determined. The mean fluorescence intensity (MFI) and PD-1+ (0, 1, 2, 4 hours) of Jurkat cells were measured against those of the untreated control. (G) TRIP12 knockdown Jurkat T cells were analyzed for NFATc1 degradation is catalyzed by E3 ligase TRIP12. (A) Proteasome inhibitor MG-132 increased NFATc1 protein levels in HEK293T cells, and ubiquitination levels of NFATc1 were detected. (I) TRIP12 knockdown with its HECT domain deleted, increased NFATc1 ubiquitination, which was further substantiated by the knockdown Jurkat T cells. (J) TRIP12 increased PD-1 expression in Jurkat cells with its HECT domain deleted. Increased expression of PD-1 was detected in Jurkat T cells and TRIP12 knockdown Jurkat T cells when Me-Trp was overexpressed with TRIP12 or TRIP12 lacking HECT domain (TRIP12-ΔHECT) in HEK293T cells, and ubiquitination levels of NFATc1 were detected. (i) TRIP12 knockdown depleted the ubiquitination of endogenous NFATc1. NFATc1 was overexpressed with co-transfection with TRIP12 or TRIP12 lacking HECT domain (TRIP12-ΔHECT) in HEK293T cells, and ubiquitination levels of NFATc1 were detected. (ii) TRIP12 knockdown depleted the ubiquitination of endogenous NFATc1. NFATc1 was overexpressed with co-transfection with TRIP12 or TRIP12 lacking HECT domain (TRIP12-ΔHECT) in HEK293T cells, and ubiquitination levels of NFATc1 were detected. (j) TRIP12 knockdown depleted the ubiquitination of endogenous NFATc1. NFATc1 was overexpressed with co-transfection with TRIP12 or TRIP12 lacking HECT domain (TRIP12-ΔHECT) in HEK293T cells, and ubiquitination levels of NFATc1 were detected.

**p<0.01, ***p<0.001.

Figure 1 Negative regulation of NFATc1 (Figure 1A, B) and selective inhibition of NFATc1 (Figure 1C, D) TRIP12 interacted with NFATc1. TRIP12 was tryptophanylated. A MS/MS spectrum from human liver protein library matched a tryptophanylated TRIP12 peptide.

Figure 2 (A) Proteasome inhibitor MG-132 increased NFATc1 protein levels in HEK293T cells, and ubiquitination levels of NFATc1 were detected. (I) TRIP12 knockdown with its HECT domain deleted, increased NFATc1 ubiquitination, which was further substantiated by the knockdown Jurkat T cells. (J) TRIP12 increased PD-1 expression in Jurkat cells with its HECT domain deleted. Increased expression of PD-1 was detected in Jurkat T cells and TRIP12 knockdown Jurkat T cells when Me-Trp was overexpressed with TRIP12 or TRIP12 lacking HECT domain (TRIP12-ΔHECT) in HEK293T cells, and ubiquitination levels of NFATc1 were detected. (ii) TRIP12 knockdown depleted the ubiquitination of endogenous NFATc1. NFATc1 was overexpressed with co-transfection with TRIP12 or TRIP12 lacking HECT domain (TRIP12-ΔHECT) in HEK293T cells, and ubiquitination levels of NFATc1 were detected. (j) TRIP12 knockdown depleted the ubiquitination of endogenous NFATc1. NFATc1 was overexpressed with co-transfection with TRIP12 or TRIP12 lacking HECT domain (TRIP12-ΔHECT) in HEK293T cells, and ubiquitination levels of NFATc1 were detected.
and online supplemental figure S4H), whose levels are positively regulated by NFATc1.

**Tryptophan activation E3 ligase activity of TRIP12**

Co-immunoprecipitation revealed that WARS interacted with TRIP12 (online supplemental figure S5A). Moreover, on probing with an antitransferase antibody (online supplemental figures S5B and S5C), WARS overexpression was found to increase tryptophanylation of TRIP12, but not a mutant TRIP12 with K1136 switched to arginine (TRIP12**K1136R**), which had very low tryptophan phosphorylation signal (figure 5A), suggesting that K1136 is the major tryptophan modification site of TRIP12, and allowed us to probe TRIP12 tryptophanylation with the pantryptophan-modifying antibody. Conversely, taking the advantage that HEK293T cells WARS KO (online supplemental figure S5D) was viable as KO other tRNA synthetases such as methionine tRNA synthetase and histidyl-tRNA synthetase 2, we were able to observe that WARS KO resulted in decreased NFATc1 ubiquitination (figure 5B) and increased NFATc1 protein levels in HEK293T cells (figure 5C). Tryptamine, a WARS inhibitor,35 which lowered TRIP12 tryptophanylation levels (online supplemental figure S5E), also decreased NFATc1 ubiquitination in HEK293T cells (online supplemental figure S5F) and increased NFATc1 protein levels in Jurkat T cells (online supplemental figure S5G). These results collectively suggest that TRIP12 lysine1136 tryptophan phosphorylation (Trp-K1136) activated its E3 activity toward NFATc1.

The levels of NFATc1 in HEK293T cells, but not in TRIP12**K1136R** knockin HEK293T cells (online supplemental figure S5H), were reduced by tryptophan supplementation (figure 5D) or WARS overexpression (figure 5E), suggesting that Trp-K1136 is the major underlying mechanism connecting tryptophan and WARS to PD-1 expression. K1136 is located between the WWE and HECT domains of TRIP12 (online supplemental figure S5I). We, therefore, hypothesized that K1136Trp enhanced the ability of TRIP12 to degrade NFATc1 by enhancing the ability of TRIP12 to recruit NFATc1. Recombinant tryptophan-mimetic TRIP12, which switch lysine 1136 of TRIP12 into tryptophan (TRIP12**K1136W**), had higher affinity than the WT TRIP12 to bind NFATc1 (figure 5F). Moreover, the affinity between TRIP12 and WARS was enhanced by Me-Trp supplementation (figure 5G), and the affinity between TRIP12 and NFATc1 was decreased by tryptophan deprivation (figure 5H), consistent with Me-Trp supplementation resulting in a dose-dependent increase in ubiquitination of NFATc1 (figure 5I), and tryptophan starvation leading to lower ubiquitination of NFATc1 (figure 5J). WARS knockdown decreased the affinity between TRIP12 and NFATc1 (figure 5K), and resulted in lower ubiquitination of NFATc1 (figure 5L). Conversely, WARS overexpression in HEK293T-WARS KO cells increased the affinity between TRIP12 and NFATc1, but not between TRIP12**K1136R** and NFATc1 (figure 5M), and resulted in higher ubiquitination of NFATc1 (figure 5N).

These results showed that K1136Trp positively regulated the E3 activity of TRIP12 toward NFATc1 by increasing TRIP12-NFATc1 interaction.

**SIRT1 removed K1136Trp**

We further investigated whether K1136Trp is dynamically regulated. NAD+-dependent sirtuins (SIRTs), namely SIRT1-SIRT7,34 can function as deaminoacylases.36 Pan-sirtuin inhibitor NAM decreased the cell surface PD-1 and PD-1 mRNA levels in anti-CD3 and anti-CD28 co-stimulated Jurkat T cells (figure 6A,B and online supplemental figure S6A). The cell surface PD-1 decreasing effects of NAM were recaptured in stimulated mouse CD8 T cells (figure 6C and online supplemental figure S6B). These results supported the possibility that K1136Trp is reversed by SIRTs. To pinpoint which SIRT possesses de-K1136Trp activity, we screened the abilities of SIRTs to reverse K1136Trp. When all SIRTs, namely SIRT1-7, were individually co-expressed with TRIP12 in HEK293T cells, SIRT1, SIRT6, and SIRT7 showed interaction with TRIP12 (figure 6D). However, only SIRT1 overexpression significantly decreased the tryptophanylation of isolated TRIP12 (figure 6E), and only SIRT1 overexpression clearly increased the surface PD-1 expression in Jurkat T cells (figure 6F and online supplemental figure S6C). These results suggested that SIRT1 is a de-tryptophanylase of K1136Trp. This notion was confirmed in SIRT1 KO C57BL/6 mice, in which decreased PD-1 expression in CD8 T cells was observed along with abrogated NAM ability to decreased surface PD-1 expression in CD8 T cells (figure 6G and online supplemental figure S6D, S6E). These results also suggest that SIRT1 is the major de-tryptophanylase of K1136Trp that regulates surface PD-1 expression.

**Increase in tryptophan modulation potentiated T cells to eliminate cancer cells**

Tryptamine, an analog of tryptophan that competitively inhibits WARS,35 reduced K1136Trp (online supplemental figure S5E) and induced the expression of cell surface PD-1 (figure 7A, online supplemental figure S7A) and PD-1 mRNA (figure 7B) in Jurkat T cells and induced surface PD-1 expression in stimulated mouse CD8 T cells (figure 7C, online supplemental figure S7B), consistent with potentiation of T cells by tryptophan phosphorylation. As CD8 T cells are the major effector cells in eliminating cancer cells,37 we examined whether tryptophan treatment could increase the cytotoxic activity of CD8 T cells, since tryptophan (figure 1H) or IDO inhibitor (figure 2D) treatment decreased the expression of PD-1 in mouse CD8 T cells. CD8 T cells were isolated from OVA-stimulated mouse according to a previously reported protocol.36 CD8 T cells were sorted from the OVA-immunized BALB/c splenocytes by surface CD3 and CD8 (online supplemental figure S7C and S7D). The ability of tryptophan to increase the toxicity of CD8 T cells was tested in LLC and mouse CT26 colorectal carcinoma cells. Tryptophan resulted in a dose-dependent increase in the
Figure 5  Tryptophanylation activates the E3 ligase activity of TRIP12. (A) Tryptophanyl-tRNA synthetase (WARS) increased TRIP12, but not TRIP12K1136R tryptophanylation. Myc-tagged TRIP12 or TRIP12K1136R was expressed alone or co-overexpressed with WARS-HA in HEK293T cells. The tryptophanylation levels of anti-myc beads purified TRIP12 and TRIP12K1136R were examined. (B) WARS knockdown decreased NFATc1 ubiquitination levels. NFATc1 was overexpressed alone or co-overexpressed with TRIP12 in WT or WARS-KO HEK293T cells. The ubiquitination levels of purified NFATc1 were detected. (C) WARS knockdown increased endogenous NFATc1 levels. The NFATc1 levels in HEK293T cells and WARS-KO HEK293T cells were detected. Ablating TRIP12 tryptophanylation site abrogated Me-Trp supplemental or WARS overexpression to decrease NFATc1. NFATc1 levels were compared between HEK293T cells and TRIP12K1136R knockin HEK293T cells that were subject to Me-Trp supplemental (D) or WARS overexpression (E). (F) Tryptophanylation mimic TRIP12K1136W had higher affinity to NFATc1 than wild-type TRIP12. Myc-tagged TRIP12 or TRIP12K1136W was each co-overexpressed with NFATc1-flag in HEK293T cells. The amount of TRIP12 or TRIP12K1136W that was co-immunoprecipitated with NFATc1 was detected. (G) Tryptophan altered the affinity between TRIP12 and WARS. FLAG-tagged TRIP12 was co-overexpressed with WARS-HA in HEK293T cells that were cultured with or without Me-Trp supplementation. The amount of WARS that was co-precipitated with TRIP12 was detected. (H) Tryptophan altered the affinity between TRIP12 and NFATc1. Flag-tagged NFATc1 was co-overexpressed with TRIP12-myc in HEK293T cells that were cultured with or without tryptophan starvation. The amount of TRIP12 that was co-precipitated with NFATc1 was detected. Tryptophan regulated the ubiquitination levels of NFATc1. NFATc1 was co-overexpressed with TRIP12 in HEK293T cells. The ubiquitination levels of NFATc1 from Me-Trp supplemented (I) and tryptophan starved (J) cells were compared with those of untreated cells. (K) WARS knockdown decreased the affinity between TRIP12 and NFATc1. Myc-tagged TRIP12 was co-overexpressed with NFATc1-Flag in HEK293T cells and in HEK293T cells with WARS knockdown. The amount of TRIP12 co-immunoprecipitated with NFATc1 was detected. (L) WARS knockdown decreased ubiquitination of NFATc1. NFATc1 was overexpressed alone or co-overexpressed with TRIP12 in HEK293T cells and in WARS knockdown HEK293T cells. The ubiquitination levels of purified NFATc1 were detected. (M) Tryptophanylation site ablation abrogated WARS to enhance TRIP12-NFATc1 interaction. The amount of Myc-tagged TRIP12 co-precipitated with NFATc1-flag was detected when they were co-overexpressed in WARS-KO HEK293T cells that were with or without WARS overexpression. Quantitation of the western blot analysis was shown. (N) WARS overexpression increased ubiquitination of NFATc1. NFATc1 was overexpressed alone or co-overexpressed with TRIP12 in WARS-KO HEK293T cells in the presence or absence of WARS overexpression. Ubiquitination levels of NFATc1 were compared.
apoptotic rate of LLC cells that were loaded with the OVA peptide (SIINFEKL) and co-cultured with CD8+ T cells at 1:10. Conversely, it had a negligible effect on the apoptotic rate of LLC that were cultured alone (figure 1:10. Conversely, it had a negligible effect on the apoptotic rate of LLC that were cultured alone (figure 6A). (B) PD-1 mRNA was examined by reverse transcription quantitative PCR (RT-qPCR) (B). (C) NAM decreased mouse CD8+ T cells surface PD-1. Naive CD8+ T cells were isolated from the spleen of BALB/c wild-type (WT) mouse and stimulated with anti-CD3/CD28 antibodies. PD-1 MFI and PD-1 positive cells were compared between NAM-untreated and NAM-treated cells. (D) TRIP12-interacting SIRTs screening. HA-tagged SIRTs was individually co-expressed with TRIP12-flag in HEK293T cells. Interaction between TRIP12 and SIRTs was assayed by co-immunoprecipitation. (E) SIRT1 decreased the tryptophanylation of isolated TRIP12. HA-tagged SIRT1, SIRT2, SIRT6, and SIRT7 were individually co-expressed with TRIP12-flag in HEK293T cells and the tryptophanylation levels of TRIP12 purified from each SIRT-expression cell were detected. (F) SIRT1 increased cell surface PD-1 expression. HA-tagged SIRT1, SIRT6, and SIRT7 were individually overexpressed in Jurkat T cells, relative PD-1 MFI and percentage of PD-1+ cells were measured. (G) SIRT1 ablation in mice prevented NAM to decrease surface PD-1 expression. Naive CD8+ T cells were isolated from the spleen of WT or SIRT1−/− C57BL/6 mice and activated. Relative PD-1 MFI and percentage of PD-1+ cells were compared between NAM-treated and NAM-untreated mouse CD8+ T cells. *P<0.05, **P<0.001; ns, not significant.

Consistent with the results of cultured cells, when LLC were injected subcutaneously into C57BL/6 mice, intraperitoneal administration of either Me-Trp or indoximod slowed down tumor growth and the combined treatment of Me-Trp and indoximod resulted in synergistic effect on tumor growth inhibition (figure 7F,G). Two observations were made in tumor grafts following Me-Trp and indoximod treatments. First, both Me-Trp and indoximod decreased the PD-1 levels of the CD8+ T cells of mice spleens (figure 7H, online supplemental figure S7J) and tumor-infiltrating lymphocytes (TIL) CD8+ T cells, while combined treatment of Me-Trp and indoximod led to greater decrease of PD-1 (figure 7I, online supplemental figure S7K). Second, the number of CD4+ and CD8+ T cells in the tumor mass of Me-Trp-treated and indoximod-treated mice was more than double that of the tumors of untreated mice (figure 7J). Me-Trp and indoximod co-treatment showed a combined effect to enhance the number of CD4+ and CD8+ T cells, suggesting that these treatments enhanced CD8+ T cells survival and their tumor mass filtration ability.

![Figure 6](image-url) SIRT1 reverses TRIP12 K1136 tryptophanylation. Nicotinamide (NAM) decreased cell surface programmed cell death protein 1 (PD-1) and PD-1 messenger RNA (mRNA) of Jurkat cells. Activated Jurkat T cells were treated with 5 mM NAM for 6 hours. PD-1 mean fluorescence intensity (MFI) and PD-1 positive cells were measured by flow cytometry (A). PD-1 mRNA was examined by reverse transcription quantitative PCR (RT-qPCR) (B). (C) NAM decreased mouse CD8+ T cells surface PD-1. Naive CD8+ T cells were isolated from the spleen of BALB/c wild-type (WT) mouse and stimulated with anti-CD3/CD28 antibodies. PD-1 MFI and PD-1 positive cells were compared between NAM-untreated and NAM-treated cells. (D) TRIP12-interacting SIRTs screening. HA-tagged SIRTs was individually co-expressed with TRIP12-flag in HEK293T cells. Interaction between TRIP12 and SIRTs was assayed by co-immunoprecipitation. (E) SIRT1 decreased the tryptophanylation of isolated TRIP12. HA-tagged SIRT1, SIRT2, SIRT6, and SIRT7 were individually co-expressed with TRIP12-flag in HEK293T cells and the tryptophanylation levels of TRIP12 purified from each SIRT-expression cell were detected. (F) SIRT1 increased cell surface PD-1 expression. HA-tagged SIRT1, SIRT6, and SIRT7 were individually overexpressed in Jurkat T cells, relative PD-1 MFI and percentage of PD-1+ cells were measured. (G) SIRT1 ablation in mice prevented NAM to decrease surface PD-1 expression. Naive CD8+ T cells were isolated from the spleen of WT or SIRT1−/− C57BL/6 mice and activated. Relative PD-1 MFI and percentage of PD-1+ cells were compared between NAM-treated and NAM-untreated mouse CD8+ T cells. *P<0.05, **P<0.001; ns, not significant.
Figure 7  Increased tryptophanylation potentiates T cells to eliminate cancer cells. Tryptamine increased cell surface PD-1 and PD-1 mRNA in Jurkat cells. Relative PD-1 MFI and percentage of PD-1⁺ cells (A) and PD-1 mRNA (B) were measured in Jurkat T cells and tryptamine-treated Jurkat T cells. n=3, mean ± SD. (C) Tryptamine increased cell surface PD-1 in mouse CD8⁺ T cells. Naïve CD8⁺ T cells were isolated from the spleen of BALB/c WT mouse and activated with anti-CD3/CD28 antibodies. Relative PD-1 MFI and percentage of PD-1⁺ cells were measured in cells treated with tryptamine as indicated. n=3, mean±SD. Tryptophan dose-dependently increased the cytotoxicity of CD8⁺ T cells. CD8⁺ T cells were isolated from OVA-immunized BALB/c mice by flow cytometry. The apoptotic rate of LLC cells (D) and CT26 cells (E) that were co-cultured with CD8⁺ T cells (CD8⁺ T cell: LLC/CT26=10:1) in media contained different levels of Me-Trp were measured. n=3, mean±SD. Intraperitoneal dose of Trp and/or indoximod elicited regression of tumor growth. Mice inoculated with the same number of LLC cells were treated by intraperitoneal dose of Me-Trp or indoximod, both Me-Trp and indoximod, or PBS (control), the growth of tumors volume (F) and the tumor sizes and weights of sacrificed mice (G) were shown. n=10, mean±SD. Intraperitoneal dose of Trp and/or indoximod decreased the PD-1 levels. Spleen CD8⁺ T cells (H) and CD8⁺ T cells of tumor-infiltrating lymphocytes (TILs, I) were isolated from PBS, intraperitoneal dose of Me-Trp (Me-Trp), indoximod, and both Me-Trp and indoximod mice groups and analyzed on day 22. Relative MFI of surface PD-1 and percentage of PD-1⁺ cells were measured by flow cytometry. See also online supplemental Figure 7G-H for the sorting of CD8⁺ T cells. n=10, mean±SD. (J) Intraperitoneal dose of Trp or indoximod increased tumor-infiltrating CD8⁺ T cells. Confocal microscopy images of CD4 (red) or CD8 (red) staining on mouse tumor sections from PBS, intraperitoneal dose of Trp (Me-Trp), indoximod, and both Me-Trp and indoximod mice groups. DAPI (blue) showed the staining of nucleus. The density per volume of the CD4 or CD8-positive cells in the tumor sections corresponding to p value was calculated. Scale bar 50 µm, n=30 (three images randomly acquired from each mouse, and ten mice each group were included), mean±SD. (K) Intraperitoneal dose of Trp and/or anti-PD-1 elicited regression of tumor growth. Mice inoculated with B16F10 cells were treated by intraperitoneal dose of Me-Trp or anti-PD-1, both Me-Trp and anti-PD-1, or PBS (control), the tumor sizes and weights of sacrificed mice were shown. n=10, mean±SD. Intraperitoneal dose of Trp or Trp combining anti-PD-1 decreased the PD-1 levels. Spleen CD8⁺ T cells (L) and CD8⁺ T cells of tumor-infiltrating lymphocytes (TILs, M) were isolated from PBS, intraperitoneal dose of Me-Trp (Me-Trp), anti-PD-1, and Me-Trp and anti-PD-1 combined mice groups and analyzed on day 14. Relative MFI of surface PD-1 and percentage of PD-1⁺ cells were measured by flow cytometry. n=10, mean±SD.
To generalize the tumor growth inhibition effects of tryptophan-supplementation by down-regulating PD-1 and activating T cells, we examined tryptophan-supplementation effects on tumor growth of B16F10 melanoma cells under with and without PD-1 antibody injection. Tryptophan decreased the growth of B16F10 tumor cells (figure 7K) and decreased surface PD-1 levels in both spleen and TIL. CD8+ T cells (figure 7L,M), suggested that tryptophan supplemental inhibits growth of cancer cells regardless of their origins. Moreover, although both tryptophan and PD-1 antibody caused tumor regression, tryptophan exerted a potency to inhibit tumor growth in mice treated with PD-1 antibody (figure 7K-M). The synergistic effects of PD-1 antibody and tryptophan supported that tryptophan exerts its antitumor effects through inhibiting PD-1.

**DISCUSSION**

The unveiling of protein aminoacylation has opened new angles for investigating the biological processes and regulatory roles of amino acids. The immune cell suppression by tryptophan has been often attributed to T cell suppression by tryptophan catabolites. In the current study, we provided evidence at various levels to show that tryptophan accumulation may also account for IDO inhibitors’ immunity boosting efficacies because tryptophan is a T cell activator. Tryptophan activates T cells by down-regulating their inhibitory protein PD-1 expression via the WARS-TRIP12-NFATc1-PD-I axis. WARS tryptophanylates and activates TRIP12, an E3 ligase of the transcription factor NFATc1 that positively regulates PD-I expression to activate T cells, and tryptophan-activated T cells can be inhibited by SIRT1, which de-tryptophanylates Trp-K1136 and reverses consequences of TRIP12 tryptophanylation. These results unveiled that tryptophan activates T cells through lysine tryptophanylation, while its catabolites inhibit T cells via other mechanisms (online supplemental figure S8). Therefore, IDO suppresses immunity by producing tryptophan catabolites and by decreasing tryptophan levels and IDO inhibitors activate immunity by reversing these two consequences.

Mounting documented studies supported our findings. Tryptophan levels are positively associated with immunity, as IFN-γ-enhanced tryptophan catabolism to deplete tryptophan exerts immune repression, although this efficacy was mainly explained by the fact that increases of the levels of tryptophan catabolites, such as quinolnic acid and 3-hydroxyanthranilic acid, can inhibit the proliferation of immune cells and promote their apoptosis. WARS levels are positively correlated with T cell activation and are consistent with our model. CD8+ T cells with increased WARS expression are able to maintain their activation status. In immune thrombocytopenia, decreased IDO expression and increased WARS expression in CD4+ and CD8+ cells have been proposed to enhance the survival of autoreactive T cells. Consistent with such hypothesis, cancer cells overexpress IDO to create a microenvironment that has both decreased tryptophan and increased tryptophan catabolites to avoid activation of T cells. In patients with rheumatoid arthritis, the increased expression of WARS mRNA may be a cause of CD8+ T cell activation. In several cancers, including gastric adenocarcinoma, and colorectal and ovarian cancers, high levels of WARS expression are associated with a favorable prognosis, likely due to the fact that WARS is a secretable protein which is rapidly secreted in response to viral infection, and elevated circulating WARS may increase tryptophanophylation levels and activate T cells, favoring tumor immune elimination. Furthermore, SIRT1 inhibitor sirtulin treatment in infected mice decreased their spleen parasite burden, and PD-1 inhibitor showed a synergistic effect, supporting that SIRT1 inhibition would phenocopy tryptophan and IDO inhibitor to activate immunity. All these observations may be explained by the activation of T cells by tryptophanylation as proposed and demonstrated in this study, although they were initially explained by various mechanisms.

Both physiological tryptophan and its catabolites are low, with tryptophan at 10–100 µM and kynurenine at 5–50 µM. Therefore, although IDO inhibitors can increase tryptophan and decrease tryptophan catabolites, both result in T cells activation, their clinical anti-cancer efficacies are suboptimal, likely due to that IDO inhibitors can hardly vary levels of tryptophan and tryptophan catabolites to extent big enough to exert sufficient immunity-boosting power. We showed that Me-Trp supplemental increased intracellular tryptophan levels and tryptophan catabolites, and activated CD8+ T cells, suggesting that the opposite effects of tryptophan and its catabolites are dependent on the relative intracellular concentrations. This can be explored in IDO inhibitor cancer therapy. Tryptophan supplemental in combination with IDO inhibitor, which may greatly increase intracellular tryptophan levels while keeping tryptophan catabolites at low levels, had much stronger ability to prevent cancer growth. Moreover, because tryptophan activates T cells by decreasing PD-1 expression, a combination of tryptophan, IDO inhibitors, and PD-1 antibodies would be expected even more powerful strategy to fight against cancer.

**Author affiliations**

1State Key Laboratory of Genetic Engineering, School of Life Sciences and Pharmacy, Qinghai University for Nationalities, Xining, China
2NHC Key Lab of Reproduction Regulation (Shanghai Institute of Planned Parenthood Research), Shanghai Key Laboratory of Metabolic Remodeling, Institute of Metabolism and Integrative Biology and Institutes of Biomedical Sciences, Shanghai, China
3Department of Cardiology, Children’s Hospital of Fudan University, Shanghai, China
4Key Laboratory for Tibet Plateau Phytochemistry of Qinghai Province, College of Pharmacy, Qinghai University for Nationalities, Xining, China

**Contributors** SZ conceived the project. YL, SZ and YH supervised experiments, analyzed the data and wrote the manuscript. RQ and CZ carried out flow cytometry experiments and mass spectrometric analysis. RQ, C-JW, WX and P-CL carried out molecular biological experiments. J-YZ designed and verified the pan-tryptophanylation antibody. YL and J-YZ carried out animal models and animal analysis. All authors discussed the results and commented on the manuscript.

Qin R, et al. J Immunother Cancer 2021;9:e002840. doi:10.1136/jitc-2021-002840
TOX promotes the exhaustion

Shimin Zhao http://orcid.org/0000-0002-3674-9107

REFERENCES

1 Wang X, He Q, Shen H, et al. TOX promotes the exhaustion of antitumor CD8 T cells by preventing PD1 degradation in hepatocellular carcinoma. J Hepatol 2018;71:31–41.

2 Okamura H, Okazaki I-M, Shimizu K, et al. PD-1 aborsts the activation trajectory of autoreactive CD8 T cells to prohibit their acquisition of effector functions. J Autoimmun 2019;105:102296.

3 Maleki Vareki S, Garrido C, Duran I. Biomarkers of response to PD-1/PD-L1 inhibition. Crit Rev Oncol Hematol 2017;116:114–24.

4 Araki K, Youngblood B, Ahmed R. Programmed cell death 1-directed immunotherapy for enhancing T-cell function. Cold Spring Harb Symp Quant Biol 2013;78:239–47.

5 Uyttenhove C, Pluotte L, Théate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by IDO. J Hepatol 2005;43:553–7.

6 Lüb S, Königsrainer A, Zieker D, et al. Id0 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. J Exp Med 2009;201:3813–17.

7 Munn DH, Zhou M, Atwood JT, et al. Prevention of alloimmune fetal rejection by tryptophan catabolism. Science 1998;281:1191–3.

8 Lüb S, Königsrainer A, Rammsense H-G, et al. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 2009;9:445–52.

9 Zhu MMT, Dancsok AR, Nielsen TO. Indoleamine dioxygenase inhibitors: clinical rationale and current development. Curr Oncol Rep 2012;14:1–6.

10 Vacchelli E, Aranda F, Eggermont A, et al. Trial Watch: IDO inhibitors in cancer therapy. Oncology 2014;3:9657994.

11 Dai W, Gupta SL. Regulation of indoleamine 2,3-dioxygenase gene expression in human fibroblasts by interferon-gamma. Upstream control region discriminates between interferon-gamma and interferon-alpha. J Biol Chem 1990;265:19871–7.

12 Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002;9:1609–77.

13 Munn DH, Sharma MD, Baban B, et al. Gcn2 kinase in T cells mediates pro-apoptotic and anergy induction in response to indoleamine-2,3-dioxygenase. Immunity 2005;23:633–9.

14 Munn DH, Shakafzadeh E, Attwood JT, et al. Induction of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999;189:1363–72.

15 Holmgard RB, Zamarin D, Munn DH, et al. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antimitotic T cell immunotherapy targeting CTLA-4. J Exp Med 2013;210:1389–402.

16 Botticelli A, Cerbelli B, Lionetto L, et al. Can IDO activity predict primary resistance to anti-PD1 treatment in NSCLC? J Transl Med 2018;16:219.

17 Ladomersky E, Zhai L, Lauing KL, et al. Advanced age increases immunosuppression in the brain and decreases immunotherapeutic efficacy in subjects with glioblastoma. Clin Cancer Res 2020;26:5232–45.

18 Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996;8:765–72.

19 He X-D, Gong W, Zhang J-N, et al. Sensing and transmitting intracellular amino acid signals through reversible lysine aminocyclations. Cell Metab 2018;27:151–66.

20 Park SG, Schimmel P, Kim S. Aminoacyl tRNA synthetases and their connections to disease. Proc Natl Acad Sci U S A 2008;105:11043–9.

21 Moellingre RE, Cravatt BF. Functional lysine modification by an intrinsically reactive primary glycolytic metabolite. Science 2013;341:549–53.

22 Vidal C, L W, Santner-Nanan B, et al. The kynurenine pathway of tryptophan degradation is activated during osteoblastogenesis. Stem Cells 2015;33:111–21.

23 Huang Q, JJ X, Wang L. miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy (Vol 11, 58, 2018). Journal of Hematology & Oncology 2018;11.

24 Liu X-Q, Lu K, Feng L-L, et al. Up-Regulated expression of indoleamine 2,3-dioxygenase in 1 non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration. Leuk Lymphoma 2014;55:405–14.

25 Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo J 1991;11:3887–95.

26 Metz R, Rust S, Duhadaway JB, et al. Ido inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel Ido effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology 2012;1:1460–8.

27 Cho J-H, Kim H-O, Kim K-S, et al. Unique features of naive CD8+ T cell activation by IL-2. J Immunol 2013;191:5559–73.

28 Xia H, Jiang W, Zhang X, et al. Elevated Level of CD4+ T Cell Immune Activation in Acutely HIV-1-Infected Stage Associates With Increased IL-2 Production and Cycling Expression, and Subsequent CD4 T Cell Preservation. Front Immunol 2018;9:616.

29 Oestreicher KJ, Yoon H, Ahmed R, et al. Nfat1 regulates PD-1 expression upon T cell activation. J Immunol 2008;181:4832–9.

30 Anamburu J, Yaffe MB, López-Rodríguez C, et al. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 1999;285:2129–33.

31 Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998;4:1053–7.

32 Schramme F, Crosignani S, Frederik K, et al. Inhibition of Tryptophan-dioxygenase activity increases the antitumor efficacy of immune checkpoint inhibitors. Cancer Immunol Res 2020;8:32–45.

33 Paley EL, Denisova G, Sokolova O, et al. Tryptamine induces tryptophanyl-tRNA synthetase-mediated neurodegeneration with neurofilibrillary tangles in human cell and mouse models. Neuromolecular Med 2007;9:55–82.

34 Anderson KA, Green MF, Huynh FK, et al. SnapShot: mammalian sirtuins. Cell 2014;158:856–866.e1.

35 Durgeau A, Virk Y, Cognac N, et al. Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy. Front Immunol 2018;9:14.

36 Oumi C-wen, Zhi M, Fuller DM, et al. Role of LAT in the granule-mediated cytotoxicity of CD8 T cells. Mol Cell Biol 2012;32:2674–84.

37 Munn DH, Meller AL. Ido in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol 2016;37:193–207.

38 Wang X-F, Wang H-S, Wang H, et al. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of TPH-1 cells. Cell Immunol 2014;289:42–8.

39 Soliman H, Mediavilla-Varela M, Antonia S, Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer J 2010;16:254–9.

40 Meller AL, Munn DH. Ido expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762–74.

41 Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: a recent perspective? Curr Opin Immunol 2009;21:240–7.

42 Boasso A, Herbeuval J-P, Hardy AW, et al. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4–Fc in human CD4+ T cells. Blood 2006;105:1576–81.

43 Finger EB, Bluestone JA. When ligand becomes receptor–tolerance via B7 signaling on DCs. Nat Immunol 2002;3:1056–7.
45 Wang C-Y, Shi Y, Min Y-N, et al. Decreased IDO activity and increased TTS expression break immune tolerance in patients with immune thrombocytopenia. J Clin Immunol 2011;31:643–9.
46 Chen J, Jun L, Shiyong C, et al. Increased TTS expression in patients with rheumatoid arthritis. Clin Exp Med 2015;15:25–30.
47 Ghanipour A, Jirström K, Pontén F, et al. The prognostic significance of tryptophanyl-tRNA synthetase in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009;18:2949–56.
48 Patil PA, Blakely AM, Lombardo KA, et al. Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma. Histopathology 2018;73:124–36.
49 Cheong J-H, Yang H-K, Kim H, et al. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis. Lancet Oncol 2018;19:629–38.
50 Ahn YH, Park S, Choi JJ, et al. Secreted tryptophanyl-tRNA synthetase as a primary defence system against infection. Nat Microbiol 2016;2:16191.
51 Roy S, Saha S, Gupta P, et al. Crosstalk of PD-1 signaling with the SIRT1/FOXO-1 axis during the progression of visceral leishmaniasis. J Cell Sci 2019;132. doi:10.1242/jcs.226274. [Epub ahead of print: 02 05 2019].